Updates on Metastatic Prostate Cancer
Updates on Metastatic Prostate Cancer is organized by Horizon CME.
Course opens: 03/15/2023
Course expires: 03/15/2024
Description:
Prostate cancer is the most common cancer in American men, with an estimated 268,490 new cases in 2022 and is the 2nd leading cause of cancer related death. During this webcast, expert faculty will discuss new theranostic data, novel therapies, and important patient considerations for the optimization of metastatic hormone sensitive and metastatic castrate resistant prostate cancer treatment.
Learning Objectives:
• Define metastatic hormone sensitive prostate cancer (mHSPC) and metastatic castration resistant prostate cancer (mCRPC)
• Discuss both clinical and patient considerations in the selection of treatment options for mHSPC, and how to optimize sequencing of current treatment options for mCRPC
• Describe new data with theranostics and updates on PARP inhibitors in mCRPC
Additional details will be posted as soon as information is available.